1 / 1

DatopotamabDeruxtecan-dlnk(Datroway)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

ASTRAZENECA AB

Formulation:

INJECTION

Validity period:

24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Datroway(DatopotamabDeruxtecan-dlnk) Instructions:Uses,Dosage, Side Effects

DATROWAY (datopotamab deruxtecan-dlnk) is a Trop-2-directed antibody-drug conjugate (ADC) that combines a humanized monoclonal antibody with a topoisomerase I inhibitor. The ADC is designed to deliver the cytotoxic agent directly to tumor cells expressing Trop-2, leading to DNA damage and cell death. It is supplied as a lyophilized powder in single-dose vials and is administered via intravenous infusion. This innovative therapy represents a targeted approach for treating advanced breast cancer in specific patient populations.

Generic name

DatopotamabDeruxtecan-dlnk(Datroway)

English name

DatopotamabDeruxtecan-dlnk

Alternative Names

Datroway

Drug prices

Indications

DATROWAY is indicated for adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (IHC 0, IHC 1+, or IHC 2+/ISH-) who have received prior endocrine-based therapy and chemotherapy in the metastatic or unresectable setting.

Therapeutic Target

Trop-2 (Trophoblast cell-surface antigen 2)

Active Ingredients

DatopotamabDeruxtecan-dlnk

Dosage form

INJECTION

specifications

100mg * 1 vial/box

Description

Dosage and Administration

Recommended dose: 6 mg/kg (maximum 540 mg for patients ≥90 kg) administered as an intravenous infusion once every 3 weeks.

Premedication with antihistamines, antipyretics, antiemetics, lubricating eye drops, and steroid mouthwash is required.

Infusion duration: 90 minutes for the first infusion, 30 minutes for subsequent infusions if tolerated.

Dose adjustments or discontinuation may be required based on the severity of adverse reactions such as ILD/pneumonitis, ocular events, or stomatitis.

CATEGORY NAVIGATION

RECOMMENDED ARTICLES

How to Use Datopotamab deruxtecan (Datroway)

Datopotamab deruxtecan (Datroway) is a Trop-2-targeted antibody-drug conjugate (ADC) indicated for the treatment of...

Monday, October 20th, 2025, 11:46

How to Purchase Datopotamab deruxtecan (Datroway)

Datopotamab deruxtecan (Datroway) is a novel Trop-2-targeted antibody-drug conjugate (ADC) co-developed by Daiichi...

Monday, October 20th, 2025, 11:40

Departments

Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology

Contact Medical Consultant

Global Drug Search

Clinical recruitment

overseas medical treatment

Remote consultation

Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.

Click to submit medical consultant

Mailbox:Info@Lucius.La

Welcome To Consult